ClearOne Chosen By Ideal TeleHealth To Provide Video And Web Collaboration For Integration Into Its eHealth Services

SALT LAKE CITY, Aug. 11, 2014-- ClearOne (NASDAQ: CLRO), a global provider of audio and visual communication solutions, announced Ideal TeleHealth, a telemedicine and remote wellness multi-solutions provider, has selected ClearOne's Spontania Media Collaboration Service Platform for its services.  Ideal TeleHealth will integrate the Media Collaboration Service Platform directly into several of their eHealth workflow services currently under development to provide telehealth consultation, care coordination, biometric telemetry, and more.

ClearOne's Media Collaboration Service Platform was uniquely architected from the ground up with third-party application integration in mind.  The award winning Spontania video and web collaboration engine, central to the Service Platform, can be easily incorporated into third-party workflow applications with its robust application programmer interfaces (APIs).  Industries such as healthcare, education, enterprise, finance, public sector, and others can take advantage of the Service Platform by integrating voice, video and web collaboration into their new or existing workflow processes.

Further differentiating the Media Collaboration Service Platform, users are empowered to take advantage of ClearOne's VMWare based Spontania, available either as a Software-as-a-Service (SaaS) or installed directly in their own premise or data center making it one-of-a-kind in the market.  Deployment flexibility includes subscription based licensing or license purchase options to suit business scalability and security needs.

"After evaluating several options available, it became clear that the Spontania solution's extensible service-oriented architecture and their APIs would allow us to go beyond where we even thought we could take this solution," said Abraham Bornstein, MD, FACC, and CEO of Ideal TeleHealth.  "Partnering with ClearOne not only provides us a comprehensive collaboration feature set but also the level of relevant integration experience required to support our team." 

"In today's collaboration environment, it's all about workflow integration and the need for the user to have all of their tools available within the environment they are comfortable with," said David Moss ClearOne's Vice President of Sales, of Media Collaboration for North & Latin America.  "Whether it's a doctor consulting a patient, a lawyer speaking to a client, or a financial advisor working a trade with an investor, these connections are best accomplished from within their familiar workflow applications. ClearOne's Media Collaboration Service Platform enables businesses to easily, affordably and seamlessly add Spontania's advanced media capability such as audio, video, and web collaborations tools directly to their applications offering greater value to their customers."

About ClearOne

ClearOne is a global company that designs, develops and sells conferencing, collaboration, streaming and digital signage solutions for voice and visual communications.  The performance and simplicity of its advanced comprehensive solutions offer unprecedented levels of functionality, reliability and scalability.  More information about the company can be found at www.clearone.com.

About Ideal TeleHealth

Ideal TeleHealth, LLC is a telemedicine and remote wellness multi-solutions provider, enhancing the quality and accuracy of healthcare worldwide The Ideal team has been involved with the development and packaging of telemedicine systems for ten years. By finding the right partners and working closely with them, we have designed multifaceted and interoperable systems enabling effective, evidence-based health maintenance and disease management solutions through technologically advanced bio-metric telemetry, safe video connectivity and individualized education. More information about the company can be found at, www.idealtelehealth.com.

This release contains "forward-looking" statements that are based on present circumstances and on ClearOne's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated.  Such forward-looking statements, including acquisitions or investments the company may make to fuel growth, the purchase of common stock under the company's stock repurchase program and any statements of the plans and objectives of management for future operations, are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements.  Such forward-looking statements are made only as of the date of this release and ClearOne assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances.  Readers should not place undue reliance on these forward-looking statements.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.